An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants
Latest Information Update: 16 Oct 2024
At a glance
- Drugs ALX-001 (Primary) ; Caffeine; Dextromethorphan; Midazolam
- Indications Alzheimer's disease; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Allyx Therapeutics
- 15 Oct 2024 According to an Allyx Therapeutics meida release, company has been awarded a $3.3 million grant from the National Institutes of Health as part of its Small Business Innovation Research Commercial Readiness Pilot program. This funding will support further investigation ALX-001 and company intends to utilize this Commercial Readiness Pilot funding to support Phase I clinical pharmacokinetic drug-drug interaction study.
- 15 Oct 2024 New trial record